Supportive care in multiple myeloma

被引:22
作者
Ludwig, Heinz [1 ]
Zojer, Niklas [1 ]
机构
[1] Ctr Oncol & Hematol, Dept Med 1, Wilhelminenspital, A-1170 Vienna, Austria
关键词
bisphosphonates; kyphoplasty; non-steroidal anti-inflammatory drugs; opioids; anemia; quality of life; erythropoietin; infectious complications; intravenous immunoglobulins; hypercalcemia;
D O I
10.1016/j.beha.2007.10.001
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
In myeloma bone disease, bisphosphonates have been shown to delay the progression of osteolytic lesions and prevent fractures. In the case of painful vertebral fractures, vertebroplasty and kyphoplasty have become standard procedures to control symptoms and restore the original height of the vertebrae. Adequate pain control is of crucial importance for the quality of life of myeloma patients, as is maintaining adequate hemoglobin levels with the use of erythropoietic growth factors. Infections should be treated aggressively in myeloma patients, as these contribute significantly to morbidity and mortality. In patients with repeated infectious complications, prophylactic measures such as long-term application of antibiotic or antiviral medication or use of intravenous immunoglobulins is recommended. The concerted action of these supportive therapies can significantly improve the wellbeing of myeloma patients in phases of disease progression as well as during phases of remission. In progressive disease, certain measures such as adequate pain control and radiotherapy can ameliorate symptoms until the therapeutic effect of systemic anti-neoplastic therapy becomes evident.
引用
收藏
页码:817 / 835
页数:19
相关论文
共 86 条
[51]  
LUDWIG H, 2007, EHA C
[52]   FILGRASTIM IN PATIENTS WITH CHEMOTHERAPY-INDUCED FEBRILE NEUTROPENIA - A DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL [J].
MAHER, DW ;
LIESCHKE, GJ ;
GREEN, M ;
BISHOP, J ;
STUARTHARRIS, R ;
WOLF, M ;
SHERIDAN, WP ;
KEFFORD, RF ;
CEBON, J ;
OLVER, I ;
MCKENDRICK, J ;
TONER, G ;
BRADSTOCK, K ;
LIESCHKE, M ;
CRUICKSHANK, S ;
TOMITA, DK ;
HOFFMAN, EW ;
FOX, RM ;
MORSTYN, G .
ANNALS OF INTERNAL MEDICINE, 1994, 121 (07) :492-501
[53]   Zoledronic acid in the treatment of hypercalcemia of malignancy: Results of the international clinical development program [J].
Major, PP ;
Coleman, RE .
SEMINARS IN ONCOLOGY, 2001, 28 (02) :17-24
[54]  
MASSAIA M, 1988, CLIN EXP IMMUNOL, V73, P214
[55]   Long-term follow-up of a prospective, double-blind, placebo-controlled randomized trial of clodronate in multiple myeloma [J].
McCloskey, EV ;
Dunn, JA ;
Kanis, JA ;
MacLennan, ICM ;
Drayson, MT .
BRITISH JOURNAL OF HAEMATOLOGY, 2001, 113 (04) :1035-1043
[56]  
McCloskey EV, 1998, BRIT J HAEMATOL, V100, P317
[57]  
MEANS RT, 1991, BLOOD, V78, P2564
[58]   Effects of long-term intravenous ibandronate therapy on skeletal-related events, survival, and bone resorption markers in patients with advanced multiple myeloma [J].
Menssen, HD ;
Sakalová, A ;
Fontana, A ;
Herrmann, Z ;
Boewer, C ;
Facon, T ;
Lichinitser, MR ;
Singer, CRJ ;
Euller-Ziegler, L ;
Wetterwald, M ;
Fiere, D ;
Hrubisko, M ;
Thiel, E ;
Delmas, PD .
JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (09) :2353-2359
[59]   COX-2 inhibitors: Cancer trials test new uses for pain drug [J].
Michalowski, J .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2002, 94 (04) :248-249
[60]   The role of recombinant erythropoietin for the treatment of anemia in multiple myeloma [J].
Musto, P .
LEUKEMIA & LYMPHOMA, 1998, 29 (3-4) :283-291